Funding for this research was provided by:
National Institute on Drug Abuse (R01-DA020742)
Received: 5 June 2019
Accepted: 16 September 2019
First Online: 12 October 2019
Ethics approval and consent to participate
: The study was approved by the Institutional Review Board at the University of Pittsburgh (REN16120111/IRB0606147). Written informed consent was obtained, using a consent form approved by the University of Pittsburgh IRB.
: Not applicable.
: SS provides consulting services on tobacco harm minimization (including nicotine replacement therapy and digital vapor products) to subsidiaries of Reynolds American Inc. SGF has worked as a consultant for pharmaceutical companies on matters relating to smoking cessation. All other authors declare that they have no conflicts of interest.